DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$90.14
-0.92 (-1.01%)
âŧ
5d:
+1.1%
30d:
+3.24%
90d:
+22.72%
WAIT
LOW Confidence
Analysis Updated: Sep 1, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: DXCM is fairly priced but lacks strong directional signals. At 5.4% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: DXCM is fairly priced but lacks strong directional signals. At 5.4% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$126.90
Based on 10.7% avg growth
INTRINSIC VALUE TODAY
$78.79
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 24.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $90.14, which is considered slightly high relative to its 30-day fair value range of $79.82 to $92.18. From a valuation perspective, the stock is trading at a premium (Forward PE: 28.9) compared to its historical average (24.6). At these levels, the market is pricing in 5.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, DXCM is in a strong uptrend. The price is currently testing key support at $87.51. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DXCM scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DXCM is in a strong uptrend. The price is currently testing key support at $87.51. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DXCM scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$79.82 -
$92.18
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
37.1%
Protect Your Profits
Holding DXCM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($94.12)
- NEUTRAL: Trading at premium valuation - market expects 5.4% growth which is achievable
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$79.82 -
$92.18
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$87.51
Resistance Level
$92.59
Current Trend
Strong Uptrend
Technical data as of
Sep 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.85
Wall Street Target
$94.12
(+4.4%)
Revenue Growth (YoY)
13.1%
Earnings Growth (YoY)
43.6%
Profit Margin
20.1%
Valuation Premium vs History
+5.4% premium
PE vs Historical
28.9 vs 24.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.4%
(market-implied from PE analysis)
1-Year Target
$95.01
(+5%)
2-Year Target
$100.14
(+11%)
3-Year Target
$105.55
(+17%)
3-Yr Target (if PE normalizes)
(PE: 29â25)
PE COMPRESSION
$89.99
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.9, Growth: 17.3%)
$145.65
(+62%)
Base:
(SPY PE: 20.1, Growth: 17.3%)
$101.47
(+13%)
Bear:
(PE: 17.1, Growth: 17.3%)
$86.25
(-4%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (36x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 35.99 | Current EPS (TTM): $2.53
Bull Case
$123.69
(+37%)
Analyst growth 23.5%, PE expands to 39.6
Base Case
$112.44
(+25%)
Market implied 23.5%, PE stable at 36.0
Bear Case
$61.92
(-31%)
Severe decline -20.0%, PE contracts to 30.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 02, 2026 4:43 AM ET
Data refreshes hourly during market hours. Next update: 5:43 AM
Data refreshes hourly during market hours. Next update: 5:43 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-04-15
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 55 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 57 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 61 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 60 BUY |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 44 HOLD |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
